While the genomic consequences of CDK12 loss in PC and other malignancies have been established with respect to features such as tandem duplications (11, 45, 47), the assessments of phenotypic alterations in mCRPCs that accompany CDK12 inactivation have not been evaluated extensively. This evidence concerns the gene CDK12 and pachyonychia congenita.